Anti-microbial Antibodies, Host Immunity, and Autoimmune Disease

Anti-microbial antibodies in celiac disease: trick or treat?

AIM To determine the prevalence of a new set of anti-glycan and anti-outer membrane protein (anti-OMP) antibodies in a Hungarian cohort of adult Celiac disease (CD) patients. METHODS 190 consecutive CD patients [M/F: 71/119, age:39.9 (SD:14.1) years], 100 healthy, and 48 gastrointestinal controls were tested for glycan anti-Saccharomyces cerevisiae (gASCA), anti-laminaribioside (ALCA), anti-c...

Antibodies testing, Immunity and immunity passport in Covid-19

The global outbreak of coronavirus disease-2019 (COVID-19) has affected most countries in the world. Our knowledge of diagnostic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is evolving, and it is important to have a clear understanding of the nature of the tests and the interpretation of their findings. In this paper, the purpose is to interpret the results of two typ...

Anti-Cardiolipin and Anti-Neutrophil Cytoplasmic Antibodies in Iranian Patients with Behcet's Disease

Background: The prevalence of anti-Neutrophil Cytoplasmic Antibodies (ANCAs) and anti-Cardiolipin Antibodies (anti-CL Ab) in Behcet’s Disease (BD) and also their roles in vascular involvement is controversial. Objective: To assess the prevalence of ANCAs and anti-CL Ab as well as their correlations with clinical manifestations in Iranian patients with BD. Methods: In this case/control study, th...

Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity

Imatinib mesylate (Gleevec) inhibits Abl1, c-Kit, and related protein tyrosine kinases (PTKs) and serves as a therapeutic for chronic myelogenous leukemia and gastrointestinal stromal tumors. Imatinib also has efficacy against various pathogens, including pathogenic mycobacteria, where it decreases bacterial load in mice, albeit at doses below those used for treating cancer. We report that imat...

Anti-Thyroxine Antibodies in Autoimmune Thyroiditis*